X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1777) 1777
Publication (241) 241
Book Review (40) 40
Book Chapter (24) 24
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1064) 1064
hepatitis c virus (1050) 1050
humans (948) 948
hepatitis c (934) 934
direct-acting antivirals (713) 713
antiviral agents - therapeutic use (689) 689
antiviral agents (587) 587
gastroenterology & hepatology (586) 586
hepatitis c, chronic - drug therapy (562) 562
ribavirin (492) 492
hepatitis (448) 448
interferon (409) 409
male (387) 387
sofosbuvir (369) 369
hepacivirus - genetics (366) 366
female (360) 360
health aspects (358) 358
middle aged (348) 348
hcv (339) 339
hepacivirus - drug effects (333) 333
genotype (325) 325
sustained virological response (320) 320
drug therapy, combination (310) 310
treatment outcome (307) 307
direct-acting antiviral agents (286) 286
infectious diseases (285) 285
hepatitis c - drug therapy (280) 280
cirrhosis (267) 267
virus-infection (255) 255
therapy (251) 251
virus diseases (251) 251
infection (248) 248
adult (233) 233
direct-acting antiviral (233) 233
liver (229) 229
care and treatment (222) 222
aged (221) 221
drug therapy (218) 218
genotype 1 infection (212) 212
analysis (211) 211
infections (210) 210
liver cirrhosis (207) 207
hepatitis c, chronic - virology (203) 203
patients (202) 202
virology (200) 200
sustained virologic response (196) 196
biological response modifiers (195) 195
viruses (189) 189
ribavirin - therapeutic use (186) 186
direct acting antivirals (183) 183
pharmacology & pharmacy (182) 182
antiviral agents - administration & dosage (180) 180
antiviral agents - adverse effects (179) 179
treatment-naive patients (165) 165
digestive system diseases (159) 159
hepatitis c, chronic - complications (152) 152
pegylated interferon (152) 152
antiviral agents - pharmacology (151) 151
protease inhibitors (148) 148
hcv infection (143) 143
hepatocellular carcinoma (142) 142
hiv (142) 142
genotype 1 (141) 141
ledipasvir (137) 137
chronic hepatitis c (136) 136
telaprevir (136) 136
daclatasvir (135) 135
hepatology (134) 134
gastroenterology and hepatology (133) 133
plus ribavirin (130) 130
genetic aspects (129) 129
medical research (128) 128
prevalence (128) 128
hepatitis-c virus (126) 126
genotypes (125) 125
medicine, experimental (118) 118
efficacy (114) 114
risk factors (113) 113
genotype & phenotype (112) 112
immunology (112) 112
liver transplantation (112) 112
fibrosis (111) 111
viral nonstructural proteins - antagonists & inhibitors (109) 109
direct‐acting antivirals (107) 107
hepatitis c - virology (107) 107
medicine & public health (107) 107
safety (107) 107
sofosbuvir - therapeutic use (107) 107
transplantation (107) 107
interferon-alpha - therapeutic use (105) 105
hepatocellular-carcinoma (103) 103
antiviral therapy (102) 102
chronic hepatitis-c (101) 101
drug resistance, viral (100) 100
recurrence (100) 100
microbiology (99) 99
mortality (97) 97
proteases (97) 97
treatment-naive (97) 97
medicine, general & internal (96) 96
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1702) 1702
Korean (36) 36
Spanish (22) 22
Hungarian (13) 13
German (8) 8
Japanese (8) 8
French (5) 5
Russian (5) 5
Chinese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Antiviral Research, ISSN 0166-3542, 08/2014, Volume 108, Issue 1, pp. 181 - 191
Journal Article
Clinical and Molecular Hepatology, ISSN 2287-2728, 2016, Volume 22, Issue 4, pp. 432 - 438
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV... 
Hepatitis C virus | Resistant associated substitutions | Direct-acting antivirals | Sofosbuvir - therapeutic use | Recurrence | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Drug Resistance, Viral | Hepacivirus - genetics | Genotype | Drug Therapy, Combination | Hepatitis C, Chronic - drug therapy | Review
Journal Article
Hepatology, ISSN 0270-9139, 01/2018, Volume 67, Issue 1, pp. 48 - 55
Journal Article